BELLUS Health Inc. BLU.TO
Jun 29, 2023, 4:00 PM EDT
52-week range unavailable
- Market cap
- 2.47B
- Profit margin
- -475500.00%
- Volume
- 28.67K
- Open
- 19.51
- Previous close
- 19.48
- Day's range
- 19.24 – 19.61
- Beta
- -0.28
Key statistics
- Enterprise value
- 1.68B
- PEG ratio
- -2.06
- Price / sales
- 110201.53
- Price / book
- 4.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -22.28%
Next earnings
Consensus EPS estimate -0.24.
About BELLUS Health Inc.
BELLUS Health Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to creating new therapeutic options for intractable chronic cough (RCC) and various other conditions characterized by heightened cough sensitivity. The company's primary investigational compound, BLU-5937, functions as a P2X3 receptor antagonist. This drug is currently progressing through Phase II clinical trials, where it is being assessed for its potential in treating both RCC and persistent itching. Founded in 1993, BELLUS Health Inc. is headquartered in Laval, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- CA
- Employees
- 74
- Website
- gsk.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on BLU.TO — it syncs with the Stock Master app.